Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A0MS
|
|||
| Former ID |
DIB000348
|
|||
| Drug Name |
BI 655066
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Chronic plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Phase 3 | [1] | |
| Ankylosing spondylitis [ICD-11: FA92.0; ICD-10: M45; ICD-9: 720] | Phase 2 | [2] | ||
| Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 2 | [1] | ||
| Psoriatic arthritis [ICD-11: FA21; ICD-9: 696] | Phase 2 | [1] | ||
| Company |
Boehringer ingelheim pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02443298) Efficacy and Safety of BI 655066 in Patients With Severe Persistent Asthma.. U.S. National Institutes of Health. | |||
| REF 3 | Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.